The new drug is an Allogeneic CAR-T Candidate for Relapsed/Refractory Multiple Myeloma... Sep 03
AEON also secures $25 Million Investment from Daewoong Pharmaceuticals... Sep 04
Biophytis receives FDA IND clearance for COVA, a phase 2/3 clinical trial with Sarconeos (BIO101) for the treatment of COVID-19 related respiratory failure... Jul 04
-Advertisements-